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To prescribe effective treatment schemes for patients with tuberculosis, more-efficient susceptibility testing
techniques for Mycobacterium tuberculosis are needed, especially in regions with multidrug resistance. Etest (AB
BIODISK, Solna, Sweden) is a simple technique that provides quantitative drug susceptibility results for M.
tuberculosis in 5 to 10 days from a culture grown at low cost. The performance of Etest was compared to that
of the reference proportion method, using 95 M. tuberculosis clinical isolates of which 42.1% (40 of 95) were
resistant to at least one antibiotic by the reference method. Overall agreement between Etest and the reference
method was 98.9% (94 of 95) for detection of multidrug resistance; for resistance to individual drugs,
agreement was 97.9% (93 of 95) for rifampin, 96.0% (92 of 95) for ethambutol, 94.7% (90 of 95) for isoniazid,
and 85.3% (81 of 95) for streptomycin. This study supports the utility of Etest for timely detection of drug
resistance in M. tuberculosis and for use in tuberculosis control programs.
Tuberculosis (TB) is a growing global health problem, both
in terms of disease burden and in terms of resistance to con-
ventional chemotherapy (7). The regions where TB is more
prevalent lack the resources to implement appropriate mea-
sures to control the disease (13); hence, it is likely that the
problem will increase further. The standard treatment of TB as
recommended by the World Health Organization (WHO) is a
multidrug regimen that includes four antibiotics (rifampin
[RIF], isoniazid [INH], pyrazinamide, and streptomycin [STR]
or ethambutol [EMB]). This treatment scheme is usually ef-
fective against Mycobacterium tuberculosis (5, 21). However, in
settings with a high frequency of drug resistance, this regimen
is ineffective and results in lower cure rates (1). The continued
use of the standard treatment when the cure rate is low main-
tains or increases the rates of resistance (13).
The bactericidal activity of both RIF and INH in killing M.
tuberculosis (30) makes these drugs most effective for standard
treatment of TB. When an M. tuberculosis strain is resistant to
at least these two antibiotics, the effectiveness of the standard
treatment is diminished by 15 to 77% (13). Therefore, resis-
tance to these two drugs (34) defines multidrug resistance
(MDR) with significant clinical impact.
The prevalence of TB in any region is influenced by biolog-
ical, behavioral, and socioeconomic factors (15). These factors
also affect the appearance of MDR TB, which is a manmade
phenomenon that originates principally through inadequate
chemotherapy (14). A declining public health infrastructure
associated with increasing levels of MDR TB (18, 19) can occur
in any country on a focal basis. The global and widespread
emergence of drug-resistant TB is supported by the fact that
MDR prevalences are 1.6% in the United States, 1.1% in the
United Kingdom, 4.6% in Argentina, 6.6% in the Dominican
Republic, and 14.4% in Latvia (23).
Early recognition and appropriate treatment have been
proven to be one of the most effective strategies to control
MDR TB (14) even in human immunodeficiency virus (HIV)-
infected populations (31). Knowledge of the drug susceptibility
pattern of the MDR clinical isolate is necessary to design and
prescribe an appropriate treatment for the patient. Suscepti-
bility testing can prevent treatment failures and thereby dimin-
ish the number of secondary cases of MDR TB (3).
The method recommended by the NCCLS for susceptibility
testing of M. tuberculosis is the modified agar proportion. The
BACTEC system (Becton Dickinson) is also widely used. The
proportion method is an inexpensive and relatively simple
technique, which provides results in 3 weeks from a cultured
isolate. The BACTEC system provides results in only 5 days
but requires expensive equipment and reagents and technical
expertise. Molecular techniques such as PCR and DNA hy-
bridization assays provide results in 24 h, but they require
specialized equipment and highly skilled personnel, and they
have not yet been developed for all known mutations and
antimycobacterial drugs (30). Cost-effective techniques that do
not depend on prior identification of the molecular mecha-
nisms of resistance are needed for the rapid diagnosis of MDR,
wherever it may prevail.
Etest (AB BIODISK, Solna, Sweden) is a recent innovation
for quantitative antibiotic susceptibility testing of a wide vari-
ety of microorganisms (24). Preliminary studies of its applica-
tion to M. tuberculosis have shown good agreement with the
reference agar proportion method and BACTEC (100, 97.5,
91.3, and 98.7% agreement for RIF, INH, EMB, and STR,
respectively) using a sample of clinical isolates with a low
frequency of resistance (4.9%; 4 of 81) (12). These results,
and the feasibility of obtaining quantitative MIC results
within 5 days at a modest cost without specialized equip-
ment, prompted further evaluation of Etest for the detection
of drug-resistant TB. In this study, the performance of Etest
relative to the proportion method was investigated using clin-
ical isolates of M. tuberculosis from patients in a population
with a high prevalence of MDR TB (4, 18, 19). To evaluate the
ability of Etest to detect MDR TB, our comparison to the
“gold standard” with isolates having a higher frequency of
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resistance would be desirable (2, 25). This is the first study in
which Etest is validated with clinical isolates of M. tuberculosis
with a high prevalence of drug resistance (45.3% [43 of 95] of
the isolates studied were resistant to at least one drug).
MATERIALS AND METHODS
Clinical isolates. A total of 95 clinical isolates of M. tuberculosis were obtained
from 95 patients from Buenaventura, Colombia (19). Patients were selected
according to their history of receiving at least 1 month of TB treatment; 37 had
records of previous treatment(s) (acquired-resistance group) and 58 did not
(primary-resistance group). The clinical isolates were grown on modified Ogawa-
Kudoh slants (26) for use in drug susceptibility testing.
M. tuberculosis reference strains. M. tuberculosis H37Rv (ATCC 27294) (sus-
ceptible to all antituberculous agents) and M. tuberculosis AWC (resistant to
INH and STR) (32) were used for quality control. Both reference strains were
used as controls in every Etest evaluation.
Susceptibility testing. Susceptibilities to INH, RIF, STR, and EMB were
determined in a double-blind manner by the proportion method and Etest.
Testing by the modified agar proportion method was performed at the Centers
for Disease Control and Prevention (CDC, Atlanta, Ga.) as recommended by
Kent and Kubica (17). The Etest was performed at the Centro Internacional de
Entrenamiento e Investigaciones Médicas (CIDEIM) as follows. Colonies of M.
tuberculosis from Ogawa-Kudoh slant cultures incubated for 3 to 4 weeks were
suspended in Middlebrook 7H9 broth (Difco, Detroit, Mich.) using 3-mm glass
beads to achieve a turbidity equivalent to a McFarland standard of 3.0 (;9 3 108
CFU/ml). Middlebrook medium was prepared and stored for up to 30 days at 4°C
and was protected from light (either sterile or during incubation). Five Middle-
brook 7H11 agar plates (100 mm) supplemented with 10% oleic acid, albumin,
dextrose, and catalase (OADC) (Difco) were inoculated by swabbing the myco-
bacterial suspension onto the agar surface. One Etest strip was placed on each
plate after 24 h of preincubation of the inoculated plate at 37°C with 5% CO2.
No strip was placed on the fifth plate, which served as a growth control. The
plates were incubated under the same conditions for 5 to 10 days, after which the
MIC was read. The MIC was the value where the growth inhibition ellipse
intersected the strip or as specified in the AB BIODISK Etest technical guide no.
6 for M. tuberculosis (1997). As a control, each experiment included susceptibility
testing of the reference strains. For the interpretation of susceptibility categories,
the following susceptibility breakpoints were utilized: #1.0, 0.2, 5.0, and 2.0
mg/ml for RIF, INH, STR, and EMB, respectively (22). Isolates with discordant
categorical results were reassessed by Etest and the proportion method, unless
the isolate was no longer viable.
To determine the reproducibility of Etest, a set of 24 strains (chosen at
random) was evaluated at least twice in separate experiments for the four drugs.
For cases where paired results were not available due to contamination, the
complete drug set was reevaluated and the values were included in the repro-
ducibility analysis.
Statistical analyses. Data were analyzed with the statistical package SPSS for
Windows, release 7.5 (SPSS, Inc.). The reproducibility of the categorical results
was described by percent agreement and the Kappa statistic, a measure of the
percent agreement beyond that expected by chance (9). The reproducibilities of
Etest MICs were evaluated by determining the reliability coefficient after con-
verting the values to log2 MIC (6) (the Pearson regression test was not used
because tests were repeated more than twice). The sensitivity, specificity, and
positive and negative predictive values (16) of Etest were determined using the
proportion method as the reference method. The positive and negative predic-
tive values were determined for several theoretical prevalences using Bayes’
theorem (16). McNemar’s test with a level of a 5 0.05 was used to determine if
the difference between the two methods was significant.
RESULTS
The reference agar proportion method identified 43.2% (41
of 95) of the isolates as resistant to at least one of the four
antibiotics. Resistance to INH was the highest at 38.9% (37 of
95), while resistances to STR, RIF, and EMB were 22.1% (21
of 95), 22.1% (21 of 95), and 7.4% (7 of 95), respectively.
Resistance to one, two, three, and four antibiotics was ob-
served in 13.7% (13 of 95), 15.7% (15 of 95), 9.5% (9 of 95),
and 4.2% (4 of 95) of the isolates, respectively. MDR was
found in 21.1% (20 of 95) of the isolates. Resistance to RIF
was strongly associated with resistance to INH (20 of the 21
RIF-resistant isolates were also resistant to INH).
Etest results were easily read and interpreted (Fig. 1) (no
differences were observed between Etest MIC interpretations
by independent readers). The percentages of agreement, sen-
sitivity, specificity, and positive and negative predictive values
for Etest were high with regard to the individual drugs and
MDR criteria (Table 1). Agreement with the proportion
method was greater for RIF, INH, and EMB than for STR.
In 22 isolates, 24 of 88 initial comparisons between the
proportion method and Etest were discordant. After blinded
retesting by both methods with these 22 isolates, only seven
discrepancies remained (Table 2). Upon retesting, the refer-
ence proportion method yielded a different categorical result
for nine of the discrepancies, while Etest yielded a different
result for eight. Thirteen of these 17 changes were from sus-
ceptible to resistant. The retest results showed higher percent-
ages of agreement than the original values (Table 1).
For the reproducibility analysis, paired results with all 24
isolates were obtained for STR only; for the other drugs only
20 of 24 were available due to contamination. In order to
analyze the reproducibility of Etest, the Kappa statistic was
determined using the categorical results, and the reliability
coefficient was determined using the MICs converted to log2
MIC. The percent agreement was high, ranging from 79 to
95%. The Kappa statistics were all above 0.4, indicating that
the Etest results are reproducible for the four antibiotics. Like-
wise, the reliability of the MICs was substantiated by reliability
coefficients between 0.88 and 0.96 (Table 3).
To establish the theoretical positive and negative predictive
values for Etest in different scenarios of drug resistance, Bayes’
theorem (16) was applied using a range of resistance preva-
lences of 0 to 42.4% as reported in 28 countries for each
antibiotic or its combinations (23). The values obtained (data
not shown) indicate that the negative predictive values varied
between 95 and 100.0% in all cases, while the positive predic-
tive values varied between 0 and 91%.
DISCUSSION
In this study of M. tuberculosis isolates with a high frequency
of drug resistance, Etest provided reproducible categorical and
quantitative results as previously reported (32). Etest had an
average of 93.0 to 93.9% sensitivity, specificity, and agreement
with the proportion method, supporting the reliability of the
method for the four drugs evaluated.
The Etest was proven to yield reproducible results using a
sample of isolates chosen randomly. However, it was observed
that when the discrepancies between Etest and the proportion
method were reevaluated, the result varied in 8 out of 24 tests
by Etest, and in 9 out of 24 tests by the proportion method.
Thirteen of 17 discrepancies varied from susceptible to resis-
tant, which might have been due to an in vitro selection of a
resistant subpopulation during subculturing. In optimal condi-
tions, the same subculture would have been used to perform
the drug susceptibility testing by both methods, but this was not
feasible, and different subcultures were used (i.e., subcultures
were performed to send the isolates to CDC), which might in
part explain the variation in the categorical results. The vari-
ation in the MICs observed between repeats (e.g., isolate 90VT
or 06EBS in Table 2), could be explained by poor growth in the
initial testing. The retest results were not used to recalculate
the specificity, sensitivity, and negative and positive predictive
values of the Etest, because such discrepant analysis is not
recommended for diagnostic techniques due to frequent over-
estimation of performance (20).
In the case of EMB, the small number of resistant cases
(7.3% [7 of 95]) limited the stability of the sensitivity estima-
tion, while the low prevalence of resistance decreased the pos-
itive predictive value (Table 1).
To effectively control TB, it is preferable to overdiagnose
resistance than to miss patients with resistant strains of M.
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tuberculosis. The positive and negative predictive values of
Etest indicate that the technique is able to accurately detect
resistance and susceptibility to the four antibiotics and their
combinations. Etest can positively impact TB control as a tool
for individual patient testing and surveillance programs in set-
tings with high resistance prevalences, in addition to its advan-
tages in shorter turnaround time, simplicity of performance,
and lower cost.
FIG. 1. Etest results for a clinical isolate of M. tuberculosis after 10 days of incubation. Resistance to RIF (MIC, .32 mg/ml) is evidenced by the presence of growth
along the strip (top left); susceptibility to INH (MIC, ,0.016 mg/ml) is evidenced by a lack of growth in the whole plate (bottom left); and an inhibition ellipse is
observed in the STR plate (top right), in which a MIC of 0.25 mg/ml (susceptible) is read. No Etest strip was placed on the control plate (bottom right). The EMB plate
is not shown here.
TABLE 1. Comparison between Etest and the reference agar proportion method
Antibiotic Agreementa Sensitivityb Specificityc PPVd NPVe Agreement
a
upon retesting
RIF 97.9 (93/95) 100.0 (21/21); 80.8–100.0 97.3 (72/74); 89.7–99.5 91.3 (21/23); 70.5–98.5 100.0 (72/72); 93.7–100 100.0 (95/95)
INH 94.7 (90/95) 94.6 (35/37); 80.5–99.1 94.8 (55/58); 84.7–98.7 92.1 (35/38); 77.5–97.9 96.5 (55/57); 86.8–99.4 97.9 (93/95)
EMB 96.0 (92/95) 85.7 (6/7); 42.0–99.2 97.7 (86/88); 91.3–99.6 75.0 (6/8); 35.6–95.5 98.9 (86/87); 92.9–99.9 100.0 (95/95)
STR 85.3 (81/95) 85.7 (18/21); 62.6–96.2 85.1 (63/74); 74.5–92.0 62.1 (18/29); 42.4–78.7 95.5 (63/66); 86.4–98.8 94.7 (90/95)
MDR (RIF
and INH)




93.7 (356/380) 93.0 (80/86); 84.9–97.1 93.9 (276/295); 90.3–96.2 81.6 (80/98); 72.3–88.5 97.9 (276/282); 95.2–99.1 98.2 (373/380)
a Percent (number of concordant results/total results).
b Ability of Etest to detect resistance, expressed as percent (number of isolates resistant by both methods/number resistant by the proportion method); 95%
confidence interval.
c Ability of Etest to detect susceptibility, expressed as percent (number of isolates susceptible by both methods/number susceptible by the proportion method); 95%
confidence interval.
d Positive predictive value, expressed as percent (number of isolates resistant by both methods/number resistant by Etest); 95% confidence interval.
e Negative predictive value, expressed as percent (number of isolates susceptible by both methods/number susceptible by Etest); 95% confidence interval.
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Good performance for RIF, as previously reported for Etest
(12, 26, 32), was also observed in this study, where agreement
was 97.9%. The proposal that testing of RIF alone may be
adequate to diagnose MDR is applicable to Etest. Using RIF
resistance as a surrogate marker for MDR (8, 11, 29, 33) was
supported by our findings, where 95.2% (20 of 21) of the
RIF-resistant M. tuberculosis isolates were MDR. Etest could
be used as a screen for MDR by testing RIF. The RIF-resistant
isolates detected should be further confirmed by Etest and/or
reference methods to determine MDR status by performing
complete susceptibility testing (including second- and third-
line drugs) to select an appropriate treatment scheme. Patients
who have RIF-sensitive isolates can be treated with the stan-
dard regimen recommended by WHO.
In settings like the Colombian port city of Buenaventura,
where resources are severely limited and the basic needs of
52.2% of the rural population are unmet (28), no routine
susceptibility testing is performed despite a high frequency of
MDR TB cases. Under such circumstances, screening for
MDR TB patients using Etest for RIF could strengthen the TB
control program. This practice would be cost-effective for sev-
eral reasons. Etest could be more easily implemented and
sustained, because it reduces the number of operator-depen-
dent variations in the preparation and dilution of each antibi-
otic. Screening for RIF resistance would reduce the number of
multidrug susceptibility tests. This strategy would allow the TB
program to diagnose MDR earlier and reduce the costly man-
agement of MDR cases by reducing the number of contacts
with MDR TB. Equally important would be the reduction in
ineffective prescriptions for standard TB treatment for MDR
TB, reducing the selection of new MDR TB strains in the
population.
The Etest offers decision makers an economically and tech-
nologically feasible means of drug susceptibility testing that
may not be possible with the proportion method. Even in
situations where resources are not the limiting factor, the Etest
offers an important advantage in time and simplicity. The re-
sults obtained with four of the first-line antibiotics in these
drug-resistant isolates encourage the development of Etest for
other first-, second-, and third-line antibiotics. The availability
of the Etest for the spectrum of antibiotics used to manage
MDR cases would facilitate the treatment and control of MDR
TB.
In conclusion, Etest was found to be a robust, sensitive, and
specific tool for the timely detection of drug resistance in
M. tuberculosis. These features support its use in TB control
programs, especially in settings with high levels of drug resis-
tance.
ACKNOWLEDGMENTS
This work was supported by the Secretarı́a de Salud del Valle del
Cauca; the Division of AIDS, STD, and Tuberculosis Laboratory Re-
search, CDC; and CIDEIM. The Young Investigator program of COL-
CIENCIAS supported M. S. Orozco.
We thank S. Brim and B. Metchock, from the Division of AIDS,
STD, and Tuberculosis Laboratory Research, CDC, for performing
the proportion method testing; N. Saravia for assistance in preparing
this report; E. Jaramillo, H. Hernández, and L. Osorio for critical
reading of the text; J. Robledo for evaluation by the proportion meth-
od of the first set of clinical isolates in the preliminary stages of the
study; and A. M. Benı́tez for the isolation and propagation of M. tu-
berculosis from patient samples. We also thank the personnel of the
Matı́as Lumumba Hospital in Buenaventura for the clinical sample
collection and dispatching and D. J. McFadden for collaboration in the
introduction of the Etest at CIDEIM.
REFERENCES
1. Bloch, A., P. Simone, and E. McRay. 1996. Preventing multi-drug resistant
tuberculosis. JAMA 275:487–489.
2. Browner, W. S., T. B. Newman, and S. R. Cummings. 1988. Designing a new
study: diagnostic tests, p. 88–97. In S. B. Hulley and S. R. Cummings
(ed.), Designing clinical research. An epidemiological approach. Williams &
Wilkins, Baltimore, Md.
3. Centers for Disease Control and Prevention. 1993. Initial therapy for tuber-
culosis in the era of multidrug resistance. Recommendations of the Advisory
Council for the Elimination of Tuberculosis. Morb. Mortal. Wkly. Rep. 42:
RR-7.
4. Centers for Disease Control and Prevention. 1998. Acquired multi-drug
resistant TB—Buenaventura, Colombia. Morb. Mortal. Wkly. Rep. 47:759–
761.
5. Crofton, J., P. Chaulet, and D. Maher. 1997. Guidelines for the management
of drug-resistant tuberculosis. WHO/TB/96.210. World Health Organization,
Geneva, Switzerland.
6. DeVellis, R. F. 1991. Scale of development. Theory and applications, p.
25–42. Applied social research methods series, vol. 26. SAGE Publications,
Inc., Newbury Park, Calif.
7. Dye, C., S. Scheele, P. Dolin, V. Pathania, and M. C. Raviglione. 1999.
Global burden of tuberculosis. Estimated incidence, prevalence, and mor-
tality by country. JAMA 282:677–686.
8. Eltringham, I. J., F. A. Drobniewski, J. A. Mangan, P. D. Butcher, and S. M.
Wilson. 1999. Evaluation of reverse transcription-PCR and a bacteriophage-
based assay for rapid phenotypic detection of rifampin resistance in clinical
TABLE 2. Isolates with discordant results between










044EB INH R/R S (0.016)/S (0.064) Discordant
032EB INH S/S R (12.0)/R (48.0) Discordant
032EB STR S/S R (128.0)/R (256.0) Discordant
015EB STR R/R S (1.5)/ND Discordant
020EBS STR S/S R (4.0)/R (96.0) Discordant
085VT STR S/S R (4.0)/ND Discordant
091VT STR S/S R (3.0)/ND Discordant
002EB INH S/ND R (0.25)/S (0.016) Concordant
043EB INH S/R R (32)/R (0.5) Concordant
090VT INH R/R S (,0.016)/R (8) Concordant
19EB STR S/ND R (4.0)/S (0.94) Concordant
090VT STR R/R S (,0.016)/R (.256) Concordant
049EB STR S/R R (6.0)/R (96) Concordant
03EBS STR S/R R (8.0)/R (.256) Concordant
05EBS STR S/R R (16)/R (.256) Concordant
06EBS STR R/R S (0.016)/R (.256) Concordant
07EBS STR R/R R (3.0)/S (0.125) Concordant
08EBS STR S/ND R (3.0)/S (0.5) Concordant
092VT STR S/R R (96)/R (96) Concordant
10EBS EMB S/R R (.256)/R (.256) Concordant
132VT EMB R/R S (0.125)/R (8) Concordant
034VT EMB S/R R (.256)/R (8) Concordant
086VT RIF S/R R (1.0)/R (1.5) Concordant
23EBS RIF S/R R (32)/R (1.0) Concordant
a R, resistant; S, sensitive; ND, not done (isolate was nonviable or contami-
nated at the time of retesting).







for MICsAgreementa Kappa indexb
RIF 20 95 (19/20) 0.79 0.9628
INH 20 80 (16/20) 0.57 0.9609
EMB 20 85 (17/20) 0.63 0.9244
STR 24 79 (19/24) 0.56 0.8802
a Agreement of categorical results in the repeats by Etest, expressed as percent
(number of repeats in agreement/total repeats).
b Values above 0.4 are considered reproducible and beyond chance (9).
c As the value approaches 1, the test is more reliable (6).
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